Magnus Hoffmann, PhD
"EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development"
Hoffmann is the Merkin Institute Fellow at the Merkin Institute for Translational Research at the California Institute of Technology. Based on his graduate work in Pamela Bjorkman’s laboratory at Caltech, he received the Milton and Francis Clauser Prize for the best PhD thesis across all disciplines, and he was awarded an NIH Director’s Early Independence Award to launch his own laboratory as an independent postdoctoral scholar at Caltech. Hoffmann’s research focuses on the development of innovative vaccine technologies and gaining a deeper understanding of the immunological mechanisms that shape vaccine-induced immune responses. He developed the EABR technology, an innovative approach to genetically encode nanoparticles for vaccine applications. This vaccine platform combines features of mRNA- and protein nanoparticle-based vaccines resulting in superior neutralizing antibody responses against original and variant SARS-CoV-2 in mice. Ongoing and future research in his group focuses on the continued optimization, evaluation, and application of this technology.
DatesSeptember 20, 2023
AudienceGladstone and UCSF
Diversity, Equity, and Inclusion
At Gladstone, we are committed to providing events and professional development activities that resonate with our community’s diverse members. Our goal is to develop creative programming that encompasses a wide variety of ideas and perspectives to inspire, educate, and engage with everyone within our walls.
We want to effect positive change through our events and activities by providing a platform for discussions on important topics related to increasing diversity and inclusiveness in the sciences.